| Literature DB >> 23243154 |
Abstract
In this issue of Blood, Sekeres et al report a phase 2 study of lenalidomide and azacitidine for higher risk myelodysplastic syndromes (MDS). High overall response and duration of response supports the concept of combination, multitargeted approaches rather than traditional chemotherapeutics for this disease.Entities:
Mesh：
Substances：
Year: 2012 PMID： 23243154 DOI： 10.1182/blood-2012-09-452755
Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113